Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB118 Monotherapy and Combination Therapy in Advanced Solid Tumors
NCT07586943Phase 2Recruiting
- Sponsor
- Kelun-Biotech
- Start
- Jun 2026
- Primary completion
- Dec 2029
- Modality
- Prophylactic Vaccines, Bispecific Antibodies, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of CR-001 in solid tumor, sponsored by Kelun-Biotech. Started Jun 2026; status: recruiting.
02
Drugs
CR-001
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07586943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07586943.